Abstract: The present invention provides a soybean anti-pod-shattering major QTLqPD05, and a mapping method and application thereof, and belongs to the field of QTL mapping. The soybean anti-pod-shattering major QTL is mapped on the chromosome 5 of soybean at a physical position between 40448596-40703417. For the method for mapping the soybean anti-pod-shattering major QTL, a SLAF marker is screened at the whole genome level of the soybean by utilizing a SLAF-seq sequencing technology, so as to explore the QTLs related to pod shattering from this population. By using a material of a RIL7 population which has pod-shattering soybean and anti-pod-shattering soybean as the parents, a high-density genetic linkage map covering the whole genome of soybean is constructed, and QTL mapping of the anti-pod-shattering trait is carried out on this population to obtain QTLs related to anti-pod-shattering.

Abstract: The present invention is focused on a method, kit and system for determining the presence or absence of minimal residual disease in a subject who has been treated for a proliferative disease wherein said method, kit and system comprise: (A) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject prior to treatment for said disease, to obtain a first list of characters reading from left to right; (B) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject after treatment for said disease, to obtain a second list of characters reading from left to right, wherein when a nucleotide sequence is mutated it is a genetic marker for said proliferative disease; (C) determining, for each second list of characters obtained in step (B), the degree of similarity, DS, with each first list of characters obtained in step (A); (D) selecting, for each second list of c

Abstract: Disclosed herein are methods for improving detection and monitoring of human diseases. The methods can be used to provide spatial and/or developmental localization of the source of each differential mutation within the body. The methods can also be used to generate a mutation map of a subject. And the mutation map can be used to monitoring state(s) of health of one or more tissues of a subject.

Abstract: A method of measuring an analyte amount in a whole blood sample, including (i) measuring the haematocrit level of the whole blood sample; (ii) measuring an analyte amount directly in the whole blood sample; and (iii) calculating a corrected analyte amount according to relation DP=Pa(DST, DH), where Dp, is the corrected analyte amount, DST is the measured analyte amount, DH is the measured haematocrit level, and Pa is a non-constant polynomial of a degree greater than or equal to 1 having as indeterminate values the measured analyte amount, DST, and the measured haematocrit level, DH, and having its polynomial coefficients depending on the analyte.

Abstract: The invention relates to control compositions for sequencing and for chemical analyses, such as analytical chemistry analyses. More particularly, the invention relates to control compositions for sequencing and for chemical analyses having at least one barcode sequence fragment and at least one universal sequence fragment, and to methods of their use.

Abstract: A method for executing computer programs in a trusted execution environment of a device is disclosed. The method includes retrieving a genomic differentiation object corresponding to a computer program that comprises a set of encoded executable instructions. The method further includes modifying the genomic differentiation object based on genomic regulation instructions (GRI) to obtain a modified genomic differentiation object, wherein the GRI were used to encode the set of encoded executable instructions of the computer program.

Abstract: The present inventors have identified specific oncogenic pathways preferentially activated in BRAF-mutated-melanoma cells and a pathway pattern that predicts resistance of BRAF-mutated melanoma to BRAF/MEK inhibitors, providing novel clinical implications for melanoma therapy. In one embodiment, a method comprises (a) testing a sample oiBRAF-mutated melanoma cells isolated from a patient and measuring the expression levels of genes expressed in the following oncogenic pathways: TNFa, EGFR, IFNa, hypoxia, IFNy, STAT3 and Myc; (b) calculating a 7-pathway activation pattern based on the measured expression levels of step (a); and (c) identifying the patient's resistance level to BRAF/MEK inhibitor treatment based on comparison of the calculated 7-pathway activation pattern to a reference.

Abstract: A method that provides a graphical indication of whether a patient will have cancer recurrence uses univariate and bivariate prognostic features that were generated as part of a minimal spanning tree (MST). The method determines the values of first and second features. A first value is measured by detecting objects in an image of tissue from the cancer patient stained with a protein-specific IHC biomarker. A second value is measured using objects marked with an mRNA-specific probe biomarker detected in the tissue. The first feature is the univariate prognostic feature for cancer recurrence in a cohort of cancer patients. A combination of the first and second features is the bivariate prognostic feature for cancer recurrence in the cohort. The first and second features are elements of the MST. Nodes of the MST represent the univariate features, edges represent the bivariate features, and edge weights represent prognostic significance of bivariate features.

Abstract: Disclosed herein are methods for improving detection and monitoring of human diseases. The methods can be used to provide spatial and/or developmental localization of the source of each differential mutation within the body. The methods can also be used to generate a mutation map of a subject. And the mutation map can be used to monitoring state(s) of health of one or more tissues of a subject.

Abstract: A single technique for determining Ct is provided that can be used for standard sigmoidal growth curves and for problematic growth curves, such as parabolic curves. The Ct value can be determined as the intersection of a line tangent to the growth curve at the maximum of the second derivative with a baseline of the growth curve. Such a Ct value is usable for sigmoidal curves and parabolic curves, and can provide linear calibration curves to achieve accuracy in determining initial concentrations of a sample.

Abstract: Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

Abstract: A method of genotyping includes applying a sample solution including a plurality of copies of a sample polynucleotide to an array of sensors. The sample polynucleotide includes a region associated with an allele. The method further includes measuring using a plurality of sensors of the array of sensors a characteristic of the region of the plurality of copies of the sample polynucleotide and determining using a computational circuitry and the measured characteristics a statistical value indicative of the allele.

Abstract: Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology.

Abstract: Disclosed herein are methods for improving detection and monitoring of human diseases. The methods can be used to provide spatial and/or developmental localization of the source of each differential mutation within the body. The methods can also be used to generate a mutation map of a subject. And the mutation map can be used to monitoring state(s) of health of one or more tissues of a subject.

Abstract: Embodiments of a method and system for improved microbiome sequencing can include: generating guide RNA complexes for a set of targets corresponding to a set of taxa associated with the microorganism-related condition; processing the biological sample with the gRNA complexes to generate microorganism nucleic acid fragments comprising a set of end regions associated with the set of targets; ligating the set of end regions with a set of adapters sharing an adapter sequence; and amplifying the set of targets based on the ligated set of end regions and a set of primers sharing a primer sequence associated with the adapter sequence.

Abstract: A system and a method for providing a model of a superstructure joining a denture and a corresponding dental arch, the method includes the steps of obtaining a first 3D representation of at least a part of a preliminary model of the denture, obtaining a second 3D representation of at least a part of the dental arch comprising dental implants, and generating a model of a superstructure based on the first 3D representation, the second 3D representation, dental implant positions and dental implant orientations.

Abstract: In at least one illustrative embodiment, a method may comprise selecting a first plurality of text strings that each represent a nucleotide sequence that was read by a massively parallel sequencing instrument, where the nucleotide sequences represented by the selected first plurality of text strings each correspond to a first target locus, comparing the selected first plurality of text strings to one another to determine an abundance count for each unique text string included in the selected first plurality of text strings, identifying a first number of unique text strings included in the selected first plurality of text strings as representing noise responses, and determining a method detection limit as a function of the abundance counts for the first number of unique text strings identified as representing noise responses.

Abstract: Methods, systems, and software are provided for validating a somatic sequence variant in a subject having a cancer condition. Sequence reads are obtained from sequencing cell-free DNA fragments in a liquid biopsy sample of the subject. Sequence reads are aligned to a reference sequence. A variant allele fragment count and locus fragment count are identified for a candidate variant that maps to a locus in the reference sequence. The variant allele fragment count is compared against a dynamic variant count threshold for the locus. The threshold is based on a pre-test odds of a positive variant call for the locus, based on the prevalence of variants in a genomic region including the locus in a cohort of subjects having the cancer condition. The somatic sequence variant in the subject is validated, or rejected, when the variant allele fragment count for the candidate variant satisfies, or does not satisfy, the threshold.

Abstract: The invention relates to a system (100) for monitoring deviations of a state of a cell culture in a bioreactor (104, 106) from a reference state of a cell culture in a reference bioreactor (102). The bioreactor comprises the same medium (M1) as the reference bioreactor.

Abstract: In one illustrative embodiment, an allelotyping method may include selecting a plurality of text strings that each represent a nucleotide sequence that was read by a massively parallel sequencing (MPS) instrument, where the nucleotide sequences represented by the selected plurality of text strings each correspond to a particular locus, comparing the selected plurality of text strings to one another to determine an abundance count for each unique text string included in the selected plurality of text strings, and determining one or more alleles for the particular locus by comparing the abundance count for each unique text string included in the selected plurality of text strings to an abundance threshold.